Overview of the cardiovascular benefit with diabetic agents and novel combination products for type 2 diabetes.

Cardiovascular (CV) disease is commonly observed in individuals with type 2 diabetes (T2D) and is associated with significant morbidity and mortality. Diabetes medications can have substantial negative or beneficial CV effects in these patients. Thus far, specific glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors have been shown to have beneficial CV effects in persons with T2D. Clinical trials are ongoing to evaluate the CV effects of investigational and recently approved diabetes medications. Additional advances through novel combination products have been shown to improve medication adherence and patient convenience. Future studies will evaluate the long-term effects of these combination products in patients with T2D.